A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer

Human Gene Therapy

Volumn 9, Issue 14, 1998, Pages 2075-2082

  Schuler, Martin ^a,d   Rochlitz, Christoph ^b   Horowitz, Jo Ann ^c   Schlegel, Jens ^a   Perruchoud, André P ^b   Kommoss, Friedrich ^a   Bolliger, Christoph T ^b   Kauczor, Hans Ulrich ^a   Dalquen, Peter ^b   Fritz, Mary Ann ^c   Swanson, Steve ^c   Herrmann, Richard ^b   Huber, Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P53;

ADENOVIRUS; ADULT; AGED; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; EXPRESSION VECTOR; FEMALE; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE;

EID: 17344365479     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.14-2075     Document Type: Article

References (8)

1. BARTER, J., BARTKOVA, J., VOJTESEK, B., STASKOVA, Z., LUKAS, J., REJTHAR, A., KOVARIK, J., MIDGLEY, C.A., GANNON, J.V., and LANE, D.P. (1991). Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6, 1699-1703.
2. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C, HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY, A., and McCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
3. BORING, C.C., SQUIRES, T.S., TONG, T., and MONTGOMERY, S. (1994). Cancer statistics, 1994. CA Cancer J. Clin. 44, 7-26.
4. CAI, D.W., MUKHOPADHYAY, T., LIU, Y., FUJIWARA, T., and ROTH, J.A. (1993). Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum. Gene Ther. 4, 617-624.
5. CELLERINO, R., TUMMARELLO, D., GUIDI, F., ISIDORI, P., RASPUGLI, M., BISCOTTINI, B., and FATATI, G. (1991). A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J. Clin. Oncol. 9, 1453-1461.
6. CRYSTAL, R.G., McELVANEY, N.G., ROSENFELD, M.A., CHU, C.S., MASTRANGELI, A., HAY, J.G., BRODY, S.L., JAFFE, H.A., EISSA, N.T., and DANEL, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet. 8, 42-51. [See comments]
7. CRYSTAL, R.G., JAFFE, A., BRODY, S., MASTRANGELI, A., McELVANEY, N.G., ROSENFELD, M., CHU, C.S., DANEL, C., HAY, J., and EISSA, T. (1995). A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus car-rying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Hum. Gene Ther. 6, 643-666.
8. DILLMAN, R.O., HERNDON, J., SEAGREN, S.L., EATON, W.L., JR., and GREEN, M.R. (1996). Improved survival in stage III nonsmall-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl. Cancer Inst. 88, 1210-1215.